AR and neoplasm: Androgen deprivation therapy (ADT), consisting of chemical or surgical castration, which is associated with androgen receptor (AR) signaling inhibition (ARSI) and possibly chemotherapy [1], is the present main therapeutic approach for metastatic hormone-sensitive prostate cancer (mHSPC) that efficiently promotes tumor control/regression [2].